002166突发公告，明起停牌

Group 1 - The core point of the news is that the controlling shareholder and actual controller of Rhine Biology, Qin Benjun, is planning to change the company's control rights, which will lead to a potential change in the controlling shareholder and actual controller [1][2] - The company has signed several agreements with Guangzhou Defu Nutrition Investment Partnership and other parties to transfer part of its shares and acquire 80% equity of Beijing Jinkangpu Food Technology Co., Ltd. [1][2] - The stock of Rhine Biology will be suspended from trading starting December 10, 2025, for a period not exceeding 10 trading days [1] Group 2 - After the completion of the transaction, Beijing Jinkangpu will become a controlling subsidiary of the company and will be included in the consolidated financial statements [2] - The transaction is expected to enhance the company's capabilities in food and beverage, as well as health products, by leveraging synergies between the two entities [2] - The current stock price of Rhine Biology is reported at 8.7 yuan per share, with a total market value of 6.452 billion yuan [3]